IMVT Logo

Immunovant, Inc. (IMVT) 

NASDAQ
Market Cap
$3.47B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
1 of 945
Rank in Industry
1 of 538

Largest Insider Buys in Sector

IMVT Insider Trading Activity

IMVT Median Price and Trade Amounts History Chart

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Insider Activity of Immunovant, Inc.

Over the last 12 months, insiders at Immunovant, Inc. have bought $336.9M and sold $9.55M worth of Immunovant, Inc. stock.

On average, over the past 5 years, insiders at Immunovant, Inc. have bought $91.7M and sold $6.2M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $336.9M.

The last purchase of 16,845,010 shares for transaction amount of $336.9M was made by Roivant Sciences Ltd. () on 2025‑01‑13.

List of Insider Buy and Sell Transactions, Immunovant, Inc.

2025-01-22SaleChief Technology Officer
2,195
0.0015%
$23.59$51,780-6.31%
2025-01-22SaleChief Medical Officer
2,657
0.0018%
$23.59$62,679-6.31%
2025-01-15SaleChief Executive Officer
8,767
0.0059%
$23.83$208,900-9.63%
2025-01-15SaleChief Medical Officer
2,383
0.0016%
$23.83$56,782-9.63%
2025-01-15SaleChief Financial Officer
2,298
0.0016%
$23.83$54,757-9.63%
2025-01-13Purchase
16.85M
10.1065%
$20.00$336.9M-2.26%
2025-01-08SaleChief Executive Officer
5,105
0.0035%
$24.10$123,031-4.46%
2025-01-08SaleChief Financial Officer
4,105
0.0028%
$24.10$98,931-4.46%
2024-12-02Saledirector
5,425
0.0037%
$28.54$154,830-14.94%
2024-12-02Saledirector
7,750
0.0052%
$28.54$221,185-14.94%
2024-11-20SaleChief Executive Officer
16,692
0.0111%
$25.45$424,811-5.27%
2024-11-20SaleChief Medical Officer
3,353
0.0022%
$25.45$85,334-5.27%
2024-11-20SaleChief Financial Officer
4,174
0.0028%
$25.45$106,228-5.27%
2024-11-20SaleChief Legal Officer
3,650
0.0024%
$25.45$92,893-5.27%
2024-10-23SaleChief Legal Officer
4,361
0.003%
$29.53$128,780-12.69%
2024-10-23SaleChief Technology Officer
2,740
0.0019%
$29.53$80,912-12.69%
2024-10-23SaleChief Medical Officer
3,189
0.0022%
$29.53$94,171-12.69%
2024-10-16SaleChief Executive Officer
9,095
0.0063%
$28.79$261,845-9.02%
2024-10-16SaleChief Medical Officer
3,188
0.0022%
$28.79$91,783-9.02%
2024-10-16SaleChief Financial Officer
3,271
0.0023%
$28.79$94,172-9.02%

Insider Historical Profitability

88.18%
Roivant Sciences Ltd.
96650341
56.9094%
$20.4160+39.82%
Salzmann PeterChief Executive Officer
964225
0.5678%
$20.41029
Butchko Julia G.Chief Development Officer
440959
0.2596%
$20.41122<0.0001%
Macias William L.Chief Medical Officer
359408
0.2116%
$20.41020
Barnett Eva ReneeChief Financial Officer
324766
0.1912%
$20.41021
Levine Mark S.Chief Legal Officer
319228
0.188%
$20.41017
Stout Jay SChief Technology Officer
139991
0.0824%
$20.4104
Geffner MichaelChief Medical Officer
132314
0.0779%
$20.4105
Hughes Douglas J.director
119585
0.0704%
$20.4111<0.0001%
Pande Atuldirector
86663
0.051%
$20.4122+99.07%
WONG RODERICKChief Executive Officer
902498
0.5314%
$20.41220+118.39%
MIGAUSKY GEORGE Vdirector
109808
0.0647%
$20.4111<0.0001%
Fromkin Andrew J.director
88658
0.0522%
$20.4111<0.0001%

IMVT Institutional Investors: Active Positions

Increased Positions95+43.38%12M+16.67%
Decreased Positions97-44.29%8M-10.41%
New Positions20New2MNew
Sold Out Positions37Sold Out3MSold Out
Total Postitions217-0.91%79M+6.26%

IMVT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$272,567.007.38%12.54M+2M+19.59%2024-09-30
Vanguard Group Inc$144,762.003.92%6.66M+149,047+2.29%2024-09-30
Blackrock, Inc.$109,855.002.97%5.05M+137,023+2.79%2024-09-30
Deep Track Capital, Lp$94,514.002.56%4.35M+1M+50.76%2024-09-30
Armistice Capital, Llc$77,134.002.09%3.55M+151,091+4.45%2024-09-30
T. Rowe Price Investment Management, Inc.$72,416.001.96%3.33M+2M+104.96%2024-09-30
State Street Corp$65,706.001.78%3.02M+303,386+11.16%2024-09-30
Perceptive Advisors Llc$51,714.001.4%2.38M+454,976+23.65%2024-09-30
Viking Global Investors Lp$50,456.001.37%2.32M00%2024-09-30
Alpine Global Management, Llc$40,930.001.11%1.88M-25,000-1.31%2024-09-30
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.